FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 6037 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Hepatic Events and Viral Kinetics in Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab. PMID 36872921 · Liver Cancer · 2023-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Enrollment of Participants From Marginalized Racial and Ethnic Groups: A Comparative Assessment of the STEADY-PD III and SURE-PD3 Trials. PMID 36865634 · Neurol Clin Pract · 2023-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Assessing the Increased Variability in Individual Lesion Kinetics During Immunotherapy: Does It Exist, and Does It Matter? PMID 36848611 · JCO Precis Oncol · 2023-Feb The record describes a secondary analysis of a Phase III randomized trial (IMvigor211) evaluating atezolizumab versus chemotherapy in urothelial carcinoma. While it is a human oncology randomized trial with a drug intervention and reports original results, it does not meet the core eligibility criterion of having a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR) as the focus of the report. The study's primary aim is to assess variability in lesion kinetics and its impact on survival modeling, not to report the trial's formal efficacy outcomes. Therefore, it is excluded as a secondary analysis without a primary time-to-event efficacy result. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| A phase III, randomised, double-blind, multi-national clinical trial comparing SB12 (proposed eculizumab biosimilar) and reference eculizumab in patients with paroxysmal nocturnal haemoglobinuria. PMID 36819188 · EJHaem · 2023-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The risk of all-cause death with dapagliflozin versus placebo: a systematic review and meta-analysis of phase III randomized controlled trials. PMID 36803188 · Expert Opin Drug Saf · 2023-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trials. PMID 36739511 · Cephalalgia · 2023-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| The likelihood of being helped or harmed as a patient-centred tool to assess cyclin dependent kinase 4/6 inhibitors clinical impact and safety in metastatic breast cancer: a systematic review and sensitivity-analysis. PMID 36713467 · EClinicalMedicine · 2023-Feb 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | no_km 0 Figure · 0 Panel · risk not_applicable |
| Efficacy and safety of imeglimin in type 2 diabetes: A systematic review and meta-analysis of randomized placebo-controlled trials. PMID 36702046 · Diabetes Metab Syndr · 2023-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Treatment selection in multi-arm multi-stage designs: With application to a postpartum haemorrhage trial. PMID 36647713 · Clin Trials · 2023-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Twelve ESMO Congress 2022 breakthroughs: practicing oncologists' perceptions and potential application on presented data. PMID 36634532 · ESMO Open · 2023-Feb The record is a narrative review article summarizing 12 trial presentations, not an original result report of a single randomized trial. It therefore fails the 'original_result' criterion. Furthermore, it does not focus on a specific drug intervention for a single trial. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial. PMID 36618081 · Lancet Reg Health Am · 2023-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of a foot self-management intervention that utilized commercially available infrared thermometers: Mixed methods research incorporating a pilot RCT. PMID 36586765 · J Tissue Viability · 2023-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis. PMID 36564284 · Ann Oncol · 2023-Feb 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis. PMID 36549170 · Breast · 2023-Feb 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| FOxTROT2: innovative trial design to evaluate the role of neoadjuvant chemotherapy for treating locally advanced colon cancer in older adults or those with frailty. PMID 36549127 · ESMO Open · 2023-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection. PMID 36544075 · Infect Dis Ther · 2023-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Management of metastatic urothelial carcinoma: Current approach, emerging agents, and future perspectives. PMID 36537831 · Urologia · 2023-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| A connection between survival multistate models and causal inference for external treatment interruptions. PMID 36464917 · Stat Methods Med Res · 2023-Feb The record is a methodological paper discussing statistical approaches (multistate models, causal inference) to handle treatment interruptions in the context of a Phase III trial (START). It does not report the original efficacy results of a drug intervention trial; instead, it uses the trial as an example to illustrate a statistical method. Therefore, it fails the 'original_result' and 'drug_intervention' criteria. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Phloroglucinol-Derived Medications are Effective in Reducing Pain and Spasms of Urinary and Biliary Tracts: Results of Phase 3 Multicentre, Open-Label, Randomized, Comparative Studies of Clinical Effectiveness and Safety. PMID 36443585 · Adv Ther · 2023-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Early intervention using written exposure therapy for PTSD and AUD symptoms following sexual assault: Description of design and methodology. PMID 36436732 · Contemp Clin Trials · 2023-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Triamcinolone Acetonide Suprachoroidal Injectable Suspension for Uveitic Macular Edema: Integrated Analysis of Two Phase 3 Studies. PMID 36399237 · Ophthalmol Ther · 2023-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency. PMID 36380045 · Pituitary · 2023-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| A Systematic Review of Published Clinical Trials in the Systemic Treatment of Adrenocortical Carcinoma: An Initiative Led on Behalf of the Global Society of Rare Genitourinary Tumors. PMID 36376169 · Clin Genitourin Cancer · 2023-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Role of Local and/or Metastasis-directed Therapy in Patients with Hormone-sensitive M1a Prostate Cancer-A Systematic Review. PMID 36372736 · Eur Urol Oncol · 2023-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Rationale and design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in patients with high-risk diabetic cardiomyopathy. PMID 36372245 · Am Heart J · 2023-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of isavuconazole against deep-seated mycoses: A phase 3, randomized, open-label study in Japan. PMID 36307059 · J Infect Chemother · 2023-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Use of endpoints in phase III randomized controlled trials for acute myeloid leukemia over the last 15 years: a systematic review. PMID 36282773 · Leuk Lymphoma · 2023-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. PMID 36270561 · Kidney Int · 2023-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A randomized phase 2b efficacy study in patients with seizure episodes with a predictable pattern using Staccato® alprazolam for rapid seizure termination. PMID 36268811 · Epilepsia · 2023-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. PMID 36200477 · Diabetes Obes Metab · 2023-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study. PMID 36168187 · Cancer Med · 2023-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Radium-223 dichloride treatment in metastatic castration-resistant prostate cancer in Finland: A real-world evidence multicenter study. PMID 36156455 · Cancer Med · 2023-Feb The record describes a retrospective, real-world, multicenter study, not a randomized controlled trial. Therefore, it does not meet the core requirement of being a randomized trial (Phase III/IIIb or Phase II/III) with a drug intervention for the primary analysis. It is excluded based on being non-randomized and not a prospective randomized trial report. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Clinical Impact of External Beam Radiotherapy for Surgically Resected Primary Retroperitoneal Liposarcoma. PMID 36115928 · Ann Surg Oncol · 2023-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Rationale and design of the phase 3a development programme (ONWARDS 1-6 trials) investigating once-weekly insulin icodec in diabetes. PMID 36106652 · Diabetes Obes Metab · 2023-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Health-related quality of life in stage III-IV melanoma treated with targeted therapy or immunotherapy: A systematic review on the adequacy of reporting and clinical issues in phase III randomized controlled trials. PMID 36030506 · Cancer Med · 2023-Feb 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of Nivolumab in patients with advanced esophageal, gastroesophageal, and gastric cancers: a meta-analysis of randomized controlled trials. PMID 36017642 · Immunopharmacol Immunotoxicol · 2023-Feb 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Skeletal Muscle-Derived Cell Implantation for the Treatment of Fecal Incontinence: A Randomized, Placebo-Controlled Study. PMID 35961517 · Clin Gastroenterol Hepatol · 2023-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Comparison Of King's Clinical Staging In Multinational Amyotrophic Lateral Sclerosis Cohorts. PMID 35852375 · Amyotroph Lateral Scler Frontotemporal Degener · 2023-Feb 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Fight INflammation to Improve outcome after aneurysmal Subarachnoid HEmorRhage (FINISHER) trial: Study protocol for a randomized controlled trial. PMID 35361026 · Int J Stroke · 2023-Feb 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| A Phase III, prospective, double-blind, randomized, placebo-controlled trial of thrombolysis in imaging-eligible, late-window patients to assess the efficacy and safety of tenecteplase (TIMELESS): Rationale and design. PMID 35262424 · Int J Stroke · 2023-Feb 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Phase 3 trial to evaluate the safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by 23-valent pneumococcal polysaccharide vaccine 6 months later, in at-risk adults 18-49 years of age (PNEU-DAY): A subgroup analysis by baseline risk factors. PMID 36864601 · Hum Vaccin Immunother · 2023-Dec-31 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Changes in primary endpoints in cancer trials. PMID 38050011 · Drug Ther Bull · 2023-Dec-27 The record is a meta-analysis/review article summarizing endpoint changes across multiple cancer trials. It is not an original Phase III/IIIb or Phase II/III randomized trial with a drug intervention and a primary/key secondary time-to-event efficacy endpoint. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Hepatitis D: A Review. PMID 37943548 · JAMA · 2023-Dec-26 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Mesenchymal stem cell-based therapy for autoimmune-related fibrotic skin diseases-systemic sclerosis and sclerodermatous graft-versus-host disease. PMID 38111001 · Stem Cell Res Ther · 2023-Dec-18 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Istaroxime for Patients with Acute Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PMID 38131989 · Diseases · 2023-Dec-17 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| The Interaction of Acute Kidney Injury with Resuscitation Strategy in Sepsis: A Secondary Analysis of a Multicenter, Phase 3, Randomized Clinical Trial (CLOVERS). PMID 37870416 · Am J Respir Crit Care Med · 2023-Dec-15 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Projecting complete redaction of clinical trial protocols (RAPTURE): redacted cross sectional study. PMID 38097263 · BMJ · 2023-Dec-14 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Fatal iatrogenic cerebral β-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer's disease. PMID 38086820 · Nat Commun · 2023-Dec-12 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Evaluation of the efficacy and safety of amustaline/glutathione pathogen-reduced RBCs in complex cardiac surgery: the Red Cell Pathogen Inactivation (ReCePI) study-protocol for a phase 3, randomized, controlled trial. PMID 38082326 · Trials · 2023-Dec-11 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Incidence and Resolution of Eribulin-Induced Peripheral Neuropathy (IRENE) in Locally Advanced or Metastatic Breast Cancer: Prospective Cohort Study. PMID 37555463 · Oncologist · 2023-Dec-11 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
H
S
B
|
严格 v3 独有 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |